UOSD di Medicina di Precisione e Senologia, Policlinico Universitario A. Gemelli
Welcome,         Profile    Billing    Logout  
 5 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fabi, Alessandra
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting
2
168
Europe
Palbociclib
Consorzio Oncotech
Metastatic Breast Cancer, Locally Advanced Breast Cancer
07/23
07/23
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting
2
49
Europe
Atezolizumab,Paclitaxel, Carboplatin
Consorzio Oncotech
Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
07/24
07/24
AZALEA, NCT06690840: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Not yet recruiting
2
45
Europe
Atezolizumab in combination with Cyclophosphamide and Vinorelbine
European Institute of Oncology
Triple Negative Breast Cancer
12/26
02/27
Neo-AGILE, NCT06259929: NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Recruiting
2
51
Europe
Abemaciclib 150 MG + Giredestrant 30 MG
Fondazione Oncotech
Breast Cancer
04/26
04/27
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
GIM21, NCT05735392: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer ( Trial)

Completed
N/A
48
Europe
Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.
Consorzio Oncotech
Metastatic Breast Cancer
01/22
01/22
GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting
N/A
1000
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
12/25
12/26
CYCLHER, NCT06243432: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Recruiting
N/A
600
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Breast Carcinoma
12/24
03/25
STILVARCA, NCT05748353: Endocrine Disruptors and Life STILe in Breast Cancer Development

Active, not recruiting
N/A
275
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Life Style, Cadmium Exposure
06/24
07/24
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
NEORISK, NCT06441240: Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.

Recruiting
N/A
933
Europe
MRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Chemotherapy Effect, Triple Negative Breast Cancer, Recurrence, Local Neoplasm, Risk Factors
12/25
03/26
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
PERGIQUAL, NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer

Recruiting
N/A
50
Europe
Sharing all key aspects associated with the quality of life in a single digital environment
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Breast Cancer
01/25
02/25
PROMETA, NCT06261918: Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Recruiting
N/A
120
Europe
Influence of metabolic syndrome on the achievement of pathological complete response
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Metabolic Syndrome
02/25
07/26
DIAMOND, NCT05919212: Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Recruiting
N/A
22
Europe
HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Breast Cancer
06/24
02/26
SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting
N/A
70
Europe
Silibinin, Sillbrain, Placebo
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
09/25
09/27
PERSEVEREX, NCT06807749: Adjuvant Treatment in Premenopausal Breast Cancer

Not yet recruiting
N/A
800
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Clinical Research Technology S.r.l.
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
09/26
09/27
IDENTITY, NCT05835739: InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2

Recruiting
N/A
78
Europe
Centro di Riferimento Oncologico - Aviano
Breast Cancer
09/25
09/35
VANDONE, ANNA MARIA
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fabi, Alessandra
YAPPETIZER, NCT03358017: Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer

Completed
2
54
Europe
Zoledronate, zoledronic acid, Atorvastatin 80mg, Standard neoadjuvant cht
Mario Negri Institute for Pharmacological Research, Associazione Italiana per la Ricerca sul Cancro
Triple Negative Breast Cancer
06/21
07/23
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Recruiting
2
168
Europe
Palbociclib
Consorzio Oncotech
Metastatic Breast Cancer, Locally Advanced Breast Cancer
07/23
07/23
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting
2
49
Europe
Atezolizumab,Paclitaxel, Carboplatin
Consorzio Oncotech
Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
07/24
07/24
AZALEA, NCT06690840: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Not yet recruiting
2
45
Europe
Atezolizumab in combination with Cyclophosphamide and Vinorelbine
European Institute of Oncology
Triple Negative Breast Cancer
12/26
02/27
Neo-AGILE, NCT06259929: NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

Recruiting
2
51
Europe
Abemaciclib 150 MG + Giredestrant 30 MG
Fondazione Oncotech
Breast Cancer
04/26
04/27
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
GIM21, NCT05735392: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer ( Trial)

Completed
N/A
48
Europe
Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.
Consorzio Oncotech
Metastatic Breast Cancer
01/22
01/22
GIM28-ELMER, NCT06894173: EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Recruiting
N/A
1000
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
12/25
12/26
CYCLHER, NCT06243432: Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Recruiting
N/A
600
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Breast Carcinoma
12/24
03/25
STILVARCA, NCT05748353: Endocrine Disruptors and Life STILe in Breast Cancer Development

Active, not recruiting
N/A
275
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Life Style, Cadmium Exposure
06/24
07/24
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
NEORISK, NCT06441240: Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.

Recruiting
N/A
933
Europe
MRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Chemotherapy Effect, Triple Negative Breast Cancer, Recurrence, Local Neoplasm, Risk Factors
12/25
03/26
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
PERGIQUAL, NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer

Recruiting
N/A
50
Europe
Sharing all key aspects associated with the quality of life in a single digital environment
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Breast Cancer
01/25
02/25
PROMETA, NCT06261918: Transcriptional and Epimetabolic Profile of Breast Carcinoma With Luminal or HER2+ or Locally Advanced Triple-negative Histotype in Patients With/Without Previous Clinical History of Metabolic Syndrome

Recruiting
N/A
120
Europe
Influence of metabolic syndrome on the achievement of pathological complete response
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer, Metabolic Syndrome
02/25
07/26
DIAMOND, NCT05919212: Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy

Recruiting
N/A
22
Europe
HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metastatic Breast Cancer
06/24
02/26
SILMET, NCT05689619: SILibinin in NSCLC and BC Patients With Single Brain METastasis

Recruiting
N/A
70
Europe
Silibinin, Sillbrain, Placebo
Azienda Ospedaliera Città della Salute e della Scienza di Torino
Brain Metastases, Adult, Non Small Cell Lung Cancer, Breast Cancer
09/25
09/27
PERSEVEREX, NCT06807749: Adjuvant Treatment in Premenopausal Breast Cancer

Not yet recruiting
N/A
800
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Clinical Research Technology S.r.l.
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
09/26
09/27
IDENTITY, NCT05835739: InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2

Recruiting
N/A
78
Europe
Centro di Riferimento Oncologico - Aviano
Breast Cancer
09/25
09/35
VANDONE, ANNA MARIA
NCT06137833: Wide Spectrum Micronutrients Supplementation in Patients with Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Recruiting
N/A
92
Europe
APPOPRTAL®, Placebo
Pharmanutra S.p.a., Latis S.r.l.
Fatigue, Breast Cancer
06/25
06/25
GIM29-GIMOMIC, NCT06871501: "Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer"

Not yet recruiting
N/A
1000
Europe
Consorzio Oncotech
Breast Cancer
05/25
11/26

Download Options